Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections
Adam J. Plaunt(Insmed (United States)), Sasha J. Rose(Insmed (United States)), Jeong Yeon Kang(Insmed (United States)), Kuan‐Ju Chen(Insmed (United States)), Daniel LaSala(Insmed (United States)), Ryan P. Heckler(Insmed (United States)), Arielle Dorfman(Insmed (United States)), Barrett T. Smith(Insmed (United States)), Donald Chun(Insmed (United States)), Veronica Viramontes(Insmed (United States)), Antonio Macaluso(Insmed (United States)), Zhili Li(Insmed (United States)), Yuchen Zhou(Insmed (United States)), Lilly Mark(Insmed (United States)), Jessica Basso(Insmed (United States)), Franziska Leifer(Insmed (United States)), Michel R. Corboz(Insmed (United States)), Richard W. Chapman(Insmed (United States)), David Cipolla(Insmed (United States)), Walter R. Perkins(Insmed (United States)), Vladimir Malinin(Insmed (United States)), Donna M. Omiatek(Insmed (United States))
Cited by 9Open Access
Abstract
Chronic pulmonary methicillin-resistant Staphylococcus aureus (MRSA) disease in cystic fibrosis (CF) has a high probability of recurrence following treatment with standard-of-care antibiotics and represents an area of unmet need associated with reduced life expectancy. We developed a lipoglycopeptide therapy customized for pulmonary delivery that not only demonstrates potent activity against planktonic MRSA, but also against protected colonies of MRSA both in biofilms and within cells, the latter of which have been linked to clinical antibiotic failure.
Related Papers
No related papers found
Powered by citation graph analysis